174 results about "Myeloid tissue" patented technology

An automatic method for analyzing nucleated bone marrow cells comprising partitioning one sample of bone marrow fluid with two samples, one sample being treated with a first lysing agent and a first staining solution and the other sample being treated with a second lysing agent and a second staining solution; and measuring each samples in a flow cytometer using a scattered light and fluoresence which enables to classify and count leukocytes, erythroid cells and lipid particles, as well as mature myeloid cells, lymphoid cells and immature myeloid cells, and to calculate the number of myeloid cells as well as the ratio of myeloid cells and erythroid cells.

The invention relates to modulating the SIRPα-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRPα polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia.

The present invention provides a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention and/or treatment of neoplastic disorders and diseases.

A method of acquiring an image biomarker suitable for prognosis of a blood-related disease, such as acute myeloid leukemia, includes the steps of: (a) acquiring physical parameter sets, each including at least two physical parameters, respectively from time-signal intensity curves, the time-signal intensity curves being respectively obtained from magnetic resonance image sets of different subjects that are diagnosed as having the blood-related disease, each of the image sets being acquired through MRI scanning using one of first and second configuration parameter sets; (b) analyzing the physical parameter sets thus acquired with reference to prognoses of the different subjects so as to obtain weight values corresponding to the physical parameters; and (c) establishing a risk score function that is a sum of products of each of the physical parameters and the corresponding weight value, wherein a risk score obtained using the risk score function serves as the image biomarker suitable for prognosis of the blood-related disease.

The present invention relates to the use of myeloid cell biomarkers for the differential diagnosis, prognosis, and monitoring of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to monitoring the effect of a treatment against renal cell carcinoma (RCC) or colorectal cancer (CRC), and establishing a prognosis of the outcome of the treatment of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to panels of cellular biomarkers for use in the above methods, in particular multicolor panels for measuring said biomarkers.

The invention belongs to the technical field of gene engineering, and discloses a primer combination for detecting gene mutation related to AML (acute myeloid leukemia) prognosis, a kit containing the primer combination and a method for detecting gene mutation related to AML prognosis. The primer combination covers all hotspot mutant sites of FLT3, NPM1, DNMT3A and CEBPA genes, and has the advantages of high specificity and wide covering range. The annealing temperatures of all the primers are close, so that the amplification stage can be completed at one time by one procedure, and the hotspot mutation can be subjected to combined parallel detection; and the detection efficiency is high. Besides, the forward and reverse amplification primers are adopted to directly carry out sequencing, and software is utilized to directly carry out mutation analysis, so that the method has the advantages of visual detection and low cost, thereby providing important references for therapeutic scheme determination and prognosis judgment of AML.

The invention discloses a novel BH3 analogue targeted to Bcl-2 family anti-apoptotic protein and application of the novel BH3 analogue. The structural general formula of the BH3 analogue is as shown in the general formula A (the general formula A can be found in specification). A thought and method of peptidomimetics is adopted, the structure of a natural BH3 peptide fragment is simplified or modified, and the novel BH3 analogue is obtained. It is proved by experiments that the compound as shown in the general formula A and the Bcl-2 family anti-apoptotic protein represent excellent binding activity on the aspect of the molecular level; and it is shown by in-vitro carcinoma cell growth inhibition experiments that the compound has a certain in-vitro growth inhibition function on the human chronic myeloid leukemia cell K562, the human promyelocytic lenukemia cell HL-60 and the human tissue cell lymphoma cell U937. It is prompted by research results that the compound can be used as a candidate drug for preventing or treating related diseases caused by expression abnormality of anti-apoptotic protein in the Bcl-2 family protein.

The invention discloses a molecular marker with a CCDC72 gene for diagnosing the multiple myeloma. An experiment shows that compared with a normal myeloid tissue, the CCDC72 gene has a large expression quantity in a multiple myeloma tissue. The invention further discloses application of the CCDC72 gene in preparation of a medicine for treating the multiple myeloma. The research achievement provides a novel clinical multiple myeloma diagnosis method, and also provides a novel medicine target for treating the multiple myeloma.

The invention provides a compound tussah pupa powder food with an anti-radiation function. The compound tussah pupa powder food is characterized by comprising full tussah pupa powder, mung bean embryo, Tuckahoe, agaric, black sesame and brown sugar; and the manufacturing process comprises the following steps of: pre-treating the tussah pupa; pre-treating the mung bean embryo; carrying out freeze drying on the mung bean embryo and the tussah pupa; respectively drying the Tuckahoe, the agaric and the black sesame; respectively crushing the full tussah pupa powder, the mung bean embryo, the Tuckahoe, the agaric, the black sesame and the brown sugar; and uniformly mixing the ingredients in parts by weight to obtain a finished product. The compound tussah pupa powder food has the advantages of scientific and reasonable formulation and no toxic and side effect; after taken by mice, the compound tussah pupa powder food is verified and shown that the micro nuclear rate in the mouse bone marrow cell is obviously reduced, the peripheral white blood cell count and bone marrow cell DNA content are obviously increased and obvious auxiliary protection effects on the radiation hazard are obtained; the manufacturing process has the advantages of simplicity, short process, convenience in operation and control and low cost; and the nutrient components of the compound tussah pupa powder food can be kept.

This invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, and a treatment of chronic myeloid leukemia (CML) by a composition comprising an effective amount of analogs and/or salts of chlorogenic acid. The analogs are preferably sodium chlorogenate (Na-Chl) or potassium or ammonium salts, which were prepared from Chlorogenic acid or its analogs.

The invention discloses a morphological feature fused microscopic image bone marrow cell counting method and system, and the method comprises the steps: 1) obtaining labeled and unlabeled bone marrow cell microscopic images, and carrying out the image preprocessing; 2) segmenting the labeled/label-free bone marrow cell microscopic image into a plurality of labeled/label-free single bone marrow cell microscopic images according to the cell segmentation marks and a watershed algorithm, and carrying out image preprocessing on the single bone marrow cell microscopic images; 3) carrying out cell nucleus and cytoplasm segmentation on the labeled and unlabeled single bone marrow cell microscopic images by using an improved maximum between-cluster variance method and an N-distance edge expansion method, and extracting morphological characteristics; 4) constructing a hybrid convolutional neural network model, and inputting the labeled single bone marrow cell microscopic image into the model for training; and 5) predicting cell categories of the unlabeled single bone marrow cell microscopic image by using the trained hybrid convolutional neural network model, and counting each cell category. The method has relatively high precision on bone marrow cell counting.

The invention discloses a continuous mature stage bone marrow cell image automatic identification method and system, and a medium. The method mainly comprises the following steps: obtaining a data set conforming to a specification; constructing a dense connection type convolutional neural network model for automatic identification of bone marrow cells through transfer learning; carrying out size normalization on the single-cell image data, and dividing a data set after image size normalization; finely adjusting hyper-parameters of the training method, performing structural parameter training on the constructed model through fine-adjusted hyper-parameter training, obtaining an optimal structural parameter model, and introducing multiple types of random data augmentation in training; and carrying out bone marrow cell recognition effect test and evaluation on the model by utilizing multi-fold cross validation. According to the invention, automatic identification or classification of the bone marrow cells in the continuous maturation stage can be realized, the identification effect is good, and the performance and accuracy of automatic identification of the bone marrow cells in the continuous maturation stage can be improved.

The invention discloses a bone marrow cell culture medium. Antibiotics and solid serum substitutes are added to a basal culture medium. The bone marrow cells cultured by the culture medium provided bythe invention can be used for chromosome preparation, and the culture medium shows the advantages of good chromosome presentation state, easiness in observation and the like, and has wide applicationprospect in the field of medical detection.

The invention discloses a bone marrow cell proliferation degree automatic grading method and system, and belongs to the technical field of computational microimaging. The method comprises the following steps: performing image acquisition on a bone marrow smear to obtain an intensity graph and a phase graph; inputting the intensity graph and the phase graph into a convolutional neural network model, and respectively counting nucleated cells and nucleless cells in the bone marrow smear through the convolutional neural network model; and calculating the ratio of nucleated cells to nucleless cellsaccording to the counting result, and obtaining the grade of the bone marrow cell proliferation degree, so as to overcome the complex problem in manual counting and provide accurate cell counting forgrading of the bone marrow cell proliferation degree.